Expression of LAIR-1 (CD305) on Human Blood Monocytes as a Marker of Hepatic Cirrhosis Progression

María Martínez-Esparza1, Antonio José Ruiz-Alcaraz1, Violeta Carmona-Martínez1

  • 1Departamento de Bioquímica, Biología Molecular (B) e Inmunología, Facultad de Medicina, IMIB and Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100 Murcia, Spain.

Insights

Monocyte LAIR-1 (leukocyte-associated immunoglobulin-like receptor 1) expression is elevated in liver cirrhosis, potentially serving as an early biomarker for liver damage. Macrophage expression in the liver was decreased in cirrhosis.

Area of Science:

  • Immunology
  • Hepatology
  • Cell Biology

Background:

  • The inhibitory receptor LAIR-1 (CD305) is implicated in inflammatory responses.
  • Its role in chronic inflammatory diseases like liver cirrhosis warrants investigation.
  • This study focuses on LAIR-1 expression in liver macrophages and blood monocytes during cirrhosis progression.

Purpose of the Study:

  • To investigate the expression of LAIR-1 on liver macrophages and blood monocytes in relation to liver cirrhosis progression.
  • To determine if LAIR-1 expression can serve as a biomarker for early detection of liver damage.

Main Methods:

  • Immunohistochemistry
  • Flow cytometry
  • Western blot analysis of LAIR-1 expression.
  • In vitro studies using HL-60 macrophages and human blood monocytes.

Main Results:

  • Decreased LAIR-1 expression on liver macrophages in cirrhotic livers, potentially due to collagen interference.
  • In vitro studies showed decreased LAIR-1 expression after differentiation and increased total content (not surface) after activation in macrophages.
  • Blood monocytes from cirrhotic patients showed significantly higher LAIR-1 expression across all subsets, particularly in intermediate monocytes.
  • In vitro monocyte activation did not increase surface LAIR-1, suggesting in vivo stimuli are crucial for the observed increase in cirrhosis.

Conclusions:

  • Elevated monocyte LAIR-1 expression in liver cirrhosis is a unique finding compared to other chronic inflammatory conditions.
  • Monocyte LAIR-1 expression may represent a novel biomarker for the early detection of liver damage in liver cirrhosis.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
221
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
562
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
266
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.3K